• Skip to primary navigation
  • Skip to main content
  • Skip to primary sidebar
  • Skip to footer
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube

International Alliance of ALS/MND Associations

  • Members' Login
  • Contact
  • Join the Alliance
  • Donate
  • What is ALS/MND
  • Find a Member Association
  • Support for PALS & CALS
    • Fundamental Rights for People with ALS/MND and Caregivers
    • Research
      • Voice Preservation
      • Open Science
      • Expanded Access
      • Understanding ALS/MND Research
      • Improving Regulatory Pathways
      • Right to Try
      • US FDA Orphan Drug Designation
      • Unproven (Off-Label) Treatments
      • Open Label Extension
    • Advocacy
      • Advocacy Toolkit
      • Emergency Preparedness Toolkit
      • Equitable Access to Therapies
      • Recommendations for Trial Sponsors
    • Clinical Care
      • Genetic Counselling & Testing
      • Mental Health Support
      • Nursing and Symptom Management
      • Nutrition and Swallowing
      • Occupational Therapy and Activities of Daily Living
      • Physiotherapy and Mobility
      • Respiratory Care
      • Speech Therapy and Communication
      • Support for Family & Caregivers
      • Technology
      • Global Clinic Locator
    • Drugs in Development
      • AB Science – Masitinib
      • BrainStorm Cell Therapeutics – NurOwn
      • Clene Nanomedicine – CNM-Au8
      • Collaborative Medicinal Development – CuATSM
      • ILB – Tikomed
      • Kadimastem – AstroRx
      • Mitsubishi Tanabe Pharma America – Oral Edaravone
      • Neuronata-R/Lenzumestrocel
      • NeuroSense – PrimeC
      • Neuvivo – NP001
      • Prilenia Therapeutics – Pridopidine
      • T Regulatory Cell Therapies
      • SOD1 Therapies & Trials
    • Approved Drugs
      • Nuedexta
      • Radicava/Edaravone
      • Riluzole/Tiglutik
      • Rozebalamin/Methylcobalamin
      • Tofersen/Qalsody
    • Drugs No Longer in Development
      • Amylyx – AMX0035
      • Collaborative Medicinal Development – CuATSM
      • Cytokinetics – Reldesemtiv
      • Orphazyme – Arimoclomol
      • TUDCA Trial
  • Support for Health Professionals
    • Breaking the News in ALS/MND
    • Diagnostic Delay (in development)
  • Events/Programs
    • Calendar of Events/Programs
    • Alliance Meeting
    • Allied Professionals Forum
    • Alliance Webinars
    • ALS/MND Connect
    • Global Day Calendar
    • March of Faces
    • Patient Fellows Program
    • Global CRLI
    • International Symposium
  • About
    • Who We Are
    • ALS/MND Health Literacy Map
    • Board of Trustees
    • Advisory Councils/Committees
      • Scientific Advisory Council
      • PALS and CALS Advisory Council
      • Innovation and Technology Council
      • Advocacy and Public Policy Forum
      • Research Directors Forum
      • Governance Committee
      • Finance Committee
    • Staff
    • History
    • Archives
      • Newsletters
      • Meetings
    • Awards
      • Student Innovation Award
      • Forbes Norris Award
      • Humanitarian Award
      • Allied Health Professional Award
  • Members
    • Member Registration
    • Forgot Password

Neuronata-R/Lenzumestrocel

Background

Neuronata-R or Lenzumestrocel is an autologous bone marrow-derived mesenchymal stem cell product for treating Amyotrophic Lateral Sclerosis (ALS) developed by Corestem Chemon. Lenzumestrocel is administered via intrathecal injection and aims to slow ALS/MND progression by targeting neuroinflammation, promoting neuroprotection and preventing motor neuron death (Corestem Chemon website).

Lenzumestrocel was conditionally approved as on orphan drug for the treatment of ALS/MND by the South Korean Ministry of Food and Drug Safety (MFDS, Republic of Korea) in 2013, expecting the data to support a potential full approval in South Korea (Oh et al., 2015).

Approved In: Commercial Name:
South Korea NeuroNata-R

Proposed Mechanism of Action

Lenzumestrocel utilizes autologous bone marrow-derived mesenchymal stem cells (MSCs), which are adult stem cells capable of self-renewal and division. The treatment is prepared extracting bone marrow from the treated person, isolating and culturing the MSCs, and mixing them with cerebrospinal fluid (CSF – collected through spinal tap) from the same individual before administering the final product via intrathecal injection. The first injection of Lenzumestrocel typically occurs about four weeks after the initial bone marrow extraction, followed by a second injection four weeks later. The treatment is thought to target several biological pathways that may stimulate the growth of new nerve cells and regulate the immune response to damaged cells. Additionally, MSCs are thought to produce a range of molecules with modulatory effects, including the release of immune-modulating factors, putatively resulting in a protective effect on motor neurons through the expression of growth factors, and an anti-inflammatory effect (Corestem Chemon press release, Oh et al., 2018).

Clinical Trials

A phase 1 open-label trial assessed the safety and practicality of administering two intrathecal injections of autologous bone marrow-derived mesenchymal stem cells (MSCs) over 12 months in eight people living with ALS/MND. Of the eight people, seven received intrathecal injections and one passed before the first administration. No serious adverse events were observed in the 12 month follow-up period (Oh et al., 2015).

Building on these results, a phase 2 randomized controlled trial with parallel groups (Clinicaltrials.gov ID: NCT01363401) was conducted in 64 participants with a 1:1 treatment to control ratio. Lenzumestrocel was considered safe and well tolerated and, when compared to the control group (n=27), people in the Lenzumestrocel treated group (n=32) showed smaller decline in their ALSFRS-R scores at the four-month (difference of 2.98; 95% CI 1.48–4.47, P < 0.001) and six-month (3.38; 95% CI 1.23–5.54, P = 0.003) marks, but no difference in the long term survival data (up to 75 months post treatment, Oh et al., 2018). Both of these trials allowed for participants to be treated with Riluzole.

In 2023, a long-term survival benefit study on 157 people within two years from diagnosis of ALS/MND and treated with Lenzumestrocel showed a higher survival probability when compared to placebo controls from the PROACT database (Nam et al., 2023). This study has a number of limitations and therefore the results from a phase 3 study are necessary to understand Lenzumestrocel’s efficacy in slowing the disease.

More recently, Corestem Chemon ran a phase 3 multicenter, randomized, double-blind, placebo-controlled trial involving 115 people living with ALS/MND (Clinicaltrials.gov ID: NCT01363401) to evaluate the safety and efficacy of Lenzumestrocel further. This study was designed to: 1) assess the long-term impact of two injections (single cycle) of Lenzumestrocel, with Group 1 receiving a single cycle at 26-day intervals 2) evaluate the long-term safety and effectiveness of multiple Lenzumestrocel injections, where Group 2 received the initial cycle followed by three additional injections spaced three months apart. A third group, Group 3 instead received the placebo injections. The primary outcome measures were monitoring of disease progression (as measured by combined assessment of function and survival, CAFS) at 6 months and 12 months as well as long term efficacy and safety evaluation up to 36 months (Nam et al., 2022). The study was run in five centers in South Korea, and, according to the Korea Biomedical Review website, the topline results from this trial showed no difference in disease progression for the groups treated with Lenzumestrocel when compared with placebo.

Dose and Administration

The dosage is 1.0 x 10^6 cells per kilogram of body weight, administered concurrently with Riluzole. The treatment involves intrathecal administration, with two injections given four weeks apart. Each pre-filled syringe contains 4.0 x 10^7 cells in 4 mL. The product should be stored in a cool place, between 2 and 8°C. The expiration date is 48 hours after manufacturing (Corestem Chemon website).

Reported Side Effects

There was no severe adverse drug reaction found during the safety assessment, lasting a year after the first administration.

Current Status

In 2023, a phase 2 study showed that two intrathecal injections of Lenzumestrocel, combined with Riluzole, slowed disease progression compared to placebo. However, given the small size of the trial, Corestem Chemon ran a phase 3 trial to evaluate its long-term safety and efficacy in people living with ALS/MND. The topline results from the Phase 3 clinical trial suggest that Lenzumestrocel may not have a strong clinical benefit. However, no peer review data was published, which makes interpretation of results challenging at this time.

Sources

Corestem Chemon website – https://corestemchemon.com/eng/business/business__product.html 

Oh et al., 2015 – https://pmc.ncbi.nlm.nih.gov/articles/PMC4449093/

Corestem Chemon press release – https://www.nature.com/articles/d43747-020-00727-8

Oh et al., 2018 – https://onlinelibrary.wiley.com/doi/10.1002/ana.25302

Nam et al., 2023 – https://pubmed.ncbi.nlm.nih.gov/37122380/ 

Nam et al., 2022 – https://pmc.ncbi.nlm.nih.gov/articles/PMC9115933/ 

Korea Biomedical Review – https://www.koreabiomed.com/news/articleView.html?idxno=26071 

International Alliance of ALS/MND Associations
February 2025


The original language of communication is English and any translation cannot be guaranteed for accuracy of messaging.

Primary Sidebar

Drugs in Development

  • AB Science – Masitinib
  • BrainStorm Cell Therapeutics – NurOwn
  • Clene Nanomedicine – CNM-Au8
  • Collaborative Medicinal Development – CuATSM
  • ILB – Tikomed
  • Kadimastem – AstroRx
  • Methylcobalamin
  • Mitsubishi Tanabe Pharma America – Oral Edaravone
  • Neuronata-R/Lenzumestrocel
  • NeuroSense – PrimeC
  • Neuvivo – NP001
  • T Regulatory Cell Therapies
  • Prilenia Therapeutics – Pridopidine
  • SOD1 Therapies & Trials

  • Ana María Zavala, FYADENMAC, Diagnosed 2019, Mexico

    Ana María Zavala, FYADENMAC, Diagnosed 2019, Mexico

  • Joanne Pratt, Diagnosed 2011 , MND Australia

    Joanne Pratt, Diagnosed 2011 , MND Australia

  • Anita Forte, Les Turner ALS Foundation, USA

    Anita Forte, Les Turner ALS Foundation, USA

  • Marcel R. Wernard, Diagnosed 2016,  ALS Patients Connected,  The Netherlands

    Marcel R. Wernard, Diagnosed 2016, ALS Patients Connected, The Netherlands

  • Emilienne Verhaegen, ALS Liga Belgium, Diagnosed 2014

    Emilienne Verhaegen, ALS Liga Belgium, Diagnosed 2014

  • Susan Anderson, Diagnosed 2014 , Hope Loves Company,  USA

    Susan Anderson, Diagnosed 2014 , Hope Loves Company, USA

  • Sharon Corosanite, Diagnosed 2014 , ALS Hope Foundation, USA

    Sharon Corosanite, Diagnosed 2014 , ALS Hope Foundation, USA

  • Fabio Carvalho, Associação Pró-Cura da ELA, Brazil

    Fabio Carvalho, Associação Pró-Cura da ELA, Brazil

  • Richard Clark, MND New Zealand,  Diagnosed 2011

    Richard Clark, MND New Zealand, Diagnosed 2011

  • Enzo Maccarrone, AISLA ONLUS, Italy

    Enzo Maccarrone, AISLA ONLUS, Italy

  • H. Todd Kelly, Diagnosed 2013 , ALS Hope Foundation, USA

    H. Todd Kelly, Diagnosed 2013 , ALS Hope Foundation, USA

  • IMG_2658

    IMG_2658

  • Olga Cosentino, Diagnosed 2013,  Asociación ELA Argentina

    Olga Cosentino, Diagnosed 2013, Asociación ELA Argentina

  • Alejandro Aquino, Diagnosed 2011 , Asociación ELA Argentina

    Alejandro Aquino, Diagnosed 2011 , Asociación ELA Argentina

  • Mark Miller

    Mark Miller

  • 83

    83

  • JP

    JP

  • Steven Gallagher, Canada

    Steven Gallagher, Canada

  • Liam Dwyer, England

    Liam Dwyer, England

  • Leon Ryba, Asociación ELA Argentina

    Leon Ryba, Asociación ELA Argentina

  • Chih Ching Darren Wong, MND Malaysia

    Chih Ching Darren Wong, MND Malaysia

  • Liong Ting Ngu, MND Malaysia, Diagnosed 2014

    Liong Ting Ngu, MND Malaysia, Diagnosed 2014

  • England-Lee-Millard, UK

    England-Lee-Millard, UK

  • Danny Reviers, Diagnosed 1979 , ALS Liga België, Belgium

    Danny Reviers, Diagnosed 1979 , ALS Liga België, Belgium

  • Mike Small, Motor Neurone Disease (MND) Association, UK

    Mike Small, Motor Neurone Disease (MND) Association, UK

  • Wiebke Braach, Deutsche Gesellschaft für Muskelkranke, Germany

    Wiebke Braach, Deutsche Gesellschaft für Muskelkranke, Germany

  • Ali Var, Turkey

    Ali Var, Turkey

  • Armando González Gómez, ACELA, Colombia

    Armando González Gómez, ACELA, Colombia

  • Elisabeth Zahnd, Switzerland

    Elisabeth Zahnd, Switzerland

  • Claudia Cominetti, Associazione conSLAncio Onlus,  Italy

    Claudia Cominetti, Associazione conSLAncio Onlus, Italy

  • Claudette Sturk, ALS Society of Canada

    Claudette Sturk, ALS Society of Canada
    Picture2

  • Hollister

    Hollister
    hollister

  • Dr Shelly Hoover

    Dr Shelly Hoover

  • Jean

    Jean
    jean

  • Ali Var, Turkey

    Ali Var, Turkey

  • Orlando Ruiz, Diagnosed 2001,  ACELA, Colombia

    Orlando Ruiz, Diagnosed 2001, ACELA, Colombia

  • Greg Heydet, ALS Hope Foundation, USA

    Greg Heydet, ALS Hope Foundation, USA

  • Verónica Isabel Castro Molina, Diagnosed 2014, Argentina

    Verónica Isabel Castro Molina, Diagnosed 2014, Argentina

  • Dawn Morton, Diagnosed 2014 , MND Scotland, UK

    Dawn Morton, Diagnosed 2014 , MND Scotland, UK

  • Liam Dwyer, England

    Liam Dwyer, England

  • Marcelo Farinelli, Diagnosed 2006, ABrELA, Brazil

    Marcelo Farinelli, Diagnosed 2006, ABrELA, Brazil

  • Ailsa Malcolm-Hutton, Diagnosed 2013,  MND Association of England, Wales and N Ireland

    Ailsa Malcolm-Hutton, Diagnosed 2013, MND Association of England, Wales and N Ireland

  • Jon Newsome, USA

    Jon Newsome, USA

  • Wendy Hendrickson, ALS Hope Foundation, USA

    Wendy Hendrickson, ALS Hope Foundation, USA

  • Bruno Leanza Mantegna, Diagnosed 1999 , AISLA Onlus, Italy

    Bruno Leanza Mantegna, Diagnosed 1999 , AISLA Onlus, Italy

  • Lachlan Terry,  MND Australia,  Diagnosed 2015

    Lachlan Terry, MND Australia, Diagnosed 2015

  • Oliver Juenke, Germany

    Oliver Juenke, Germany

  • Bjarne Hytjanstorp, ALS Norge, Norway

    Bjarne Hytjanstorp, ALS Norge, Norway

  • 727747090571358167

    727747090571358167

  • Chun Ju Xiao, China

    Chun Ju Xiao, China

Learn more about the March of Faces

Latest Tweets

  • Just now

Footer

Subscribe to our Bi-Monthly Newsletter

Sign up to receive updates and to hear what's going on in the International Alliance of ALS/MND Associations.

"*" indicates required fields

 
This field is for validation purposes and should be left unchanged.
  • Email
  • Facebook
  • LinkedIn
  • Twitter
  • YouTube
Return to top of page

Contact | Disclaimer | Privacy Notice & Cookies | Sitemap

Copyright © 2025 The International Alliance of ALS/MND Associations. All rights reserved.


Registered in England: Charity Number 1079504 · Site built by graphics.coop · Powered by WordPress · Members' login